Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
It is intended to be administered by subcutaneous, intramuscular, or intravenous injection
AOD 9604 is relatively affordable in the peptide world
Gastrointestinal symptoms: Some peptides, especially GLP-1 receptor agonists such as semaglutide or tirzepatide, can slow digestion, which may lead to nausea, vomiting, diarrhea, or constipation
8-12 hours IM) Preferred by 64% of patients who've tried both Intramuscular (into deltoid or vastus lateralis, using a 22-25 gauge, 1-inch needle): 41% report injection-site soreness Faster absorption More difficult self-administration for some sites (deltoid requires non-dominant arm injection) Preferred by 36% of patients who've tried both The efficacy difference is minimal
